Browse > Article

Comparative Analysis of the Seriousness of the Adverse Events and Risk of Targeted Therapy for Metastatic Renal Cell Carcinoma Among Medical Professionals  

Park, Mi-Hae (Graduate School of Clinical Pharmacy, Sookmyung Women's University)
Rhee, Jin-Nie (Graduate School of Clinical Pharmacy, Sookmyung Women's University)
Lee, Eui-Kyung (Graduate School of Clinical Pharmacy, Sookmyung Women's University)
Publication Information
Korean Journal of Clinical Pharmacy / v.21, no.2, 2011 , pp. 100-105 More about this Journal
Abstract
The perception of the 20 adverse events of targeted therapy for metastatic renal cell carcinoma was compared among medical professionals. Thirty-seven oncologists, 167 nurses and 79 pharmacists participated in the survey, and the response rate was 61.9%, 98.2%, 84.9%, respectively. Results showed that the most serious adverse event was GI perforation (8.83 points, 10 being the most serious), whereas the least serious was anemia (5.32 points). There were significant differences among oncologists, nurses and pharmacists especially for the moderately-serious adverse event such as wound-healing complication and lymphopenia. Adverse Events Composite Score (AECS) for each targeted therapy was calculated by multiplying adverse event incidence rate and seriousness score. Sunitinib had the highest score at 6.86 point and bevacizumab had the lowest at 2.1. Among professional groups oncologists showed the lowest AECS, whereas nurses had the highest. The gap on the perception of the adverse events among medical professionals needs to be reduced to get better outcomes of medical therapies for cancer patients.
Keywords
metastatic renal cell carcinoma; targeted therapy; adverse drug event; seriousness; risk;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996; 335: 865-75.   DOI   ScienceOn
2 McDermott DF. Update on the application of interleukin-2 in the treatment of renal cell carcinoma. Clin Cancer Res 2007; 13: 716s-20s.   DOI   ScienceOn
3 Molina AM, Motzer RJ. Clinical Practice Guidelines for the Treatment of Metastatic Renal Cell Carcinoma: Today and Tomorrow. The oncologist 2011; 16:45.   DOI   ScienceOn
4 Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008; 13: 1084-96.   DOI   ScienceOn
5 Thompson Coon J, Hoyle M, Green C, et al., Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess 2010; 14: 1-184, iii-iv.
6 World Health Organization (WHO), Benefit-Risk Balance for Marketed Drugs: Evaluating Safety Signals, In: Report of CIOMS Working Group IV; Geneva: 1998.
7 Escudier B, Pluzanska A, Koralewski P, et al., Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007; 370: 2103-11.   DOI   ScienceOn
8 Hudes G, Carducci M, Tomczak P, et al., Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-81   DOI   ScienceOn
9 Motzer RJ, Hutson TE, Tomczak P, et al., Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. Clin Oncol 2009; 27: 3584-90.   DOI   ScienceOn
10 Mickisch G, Gore M, Escudier B, Procopio G, Walzer S, Nuijten M. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br J Cancer 2010; 102: 80-6.   DOI   ScienceOn